Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Clinical Trial
Official title:
A Single-Arm, Open-Label, Dose Escalation Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN201 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
This study aims to provide a basis for further clinical development of CN201.
This study is the first-in-human clinical trial of CN201 to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary efficacy of CN201 in patients with relapsed or refractory B-NHL. This study will provide a basis for further clinical development of CN201. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05105867 -
CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies
|
Early Phase 1 | |
| Active, not recruiting |
NCT05008055 -
Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
|
Phase 2 | |
| Recruiting |
NCT02134262 -
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT05797948 -
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
|
N/A |